Loading...
Loading...

Go to the content (press return)

Unraveling response to temozolomide in preclinical GL261 glioblastoma with MRI/MRSI using radiomics and signal source extraction

Author
Nuñez, L.; Romero, E.; Julia, M.; Ledesma, M.; Santos, A.; Arus, C.; Candiota, A.; Vellido, A.
Type of activity
Journal article
Journal
Scientific reports
Date of publication
2020-11-12
Volume
10
Number
article 19699
First page
1
Last page
13
DOI
10.1038/s41598-020-76686-y
Project funding
Computational Intelligence for Knowledge Discovery from G Protein-Coupled Receptors
Repository
http://hdl.handle.net/2117/336171 Open in new window
URL
https://www.nature.com/articles/s41598-020-76686-y Open in new window
Abstract
Glioblastoma is the most frequent aggressive primary brain tumor amongst human adults. Its standard treatment involves chemotherapy, for which the drug temozolomide is a common choice. These are heterogeneous and variable tumors which might benefit from personalized, data-based therapy strategies, and for which there is room for improvement in therapy response follow-up, investigated with preclinical models. This study addresses a preclinical question that involves distinguishing between treated...
Citation
Nuñez, L. [et al.]. Unraveling response to temozolomide in preclinical GL261 glioblastoma with MRI/MRSI using radiomics and signal source extraction. "Scientific reports", 12 Novembre 2020, vol. 10, article 19699, p. 1-13.
Keywords
Cerebral blood volume, Glioblastoma, N Acetylaspartic acid
Group of research
IDEAI-UPC - Intelligent Data Science and Artificial Intelligence Research Center
SOCO - Soft Computing

Participants

  • Nuñez Vivero, Luis Miguel  (author)
  • Romero Merino, Enrique  (author)
  • Julia Sape, Margarida  (author)
  • Ledesma Carballo, María Jesús  (author)
  • Santos, Andrés  (author)
  • Arus Caraltó, Carles  (author)
  • Candiota Silveira, Ana Paula  (author)
  • Vellido Alcacena, Alfredo  (author)

Attachments